These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32732069)

  • 1. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
    McManus C; Oh A; Lee JA; Hur C; Kuo JH
    Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics.
    van der Plas WY; Engelsman AF; Umakanthan M; Mather A; Sidhu SB; Delbridge LW; Pollock C; Waugh D; Sywak MS; Kruijff S
    Surgery; 2019 Jan; 165(1):135-141. PubMed ID: 30413324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review.
    van der Plas WY; Dulfer RR; Engelsman AF; Vogt L; de Borst MH; van Ginhoven TM; Kruijff S;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1902-1908. PubMed ID: 28402557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients.
    Wang AX; Liu S; Montez-Rath ME; Chertow GM; Lenihan CR
    Am J Kidney Dis; 2023 Mar; 81(3):270-280.e1. PubMed ID: 36162617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism.
    van der Plas WY; Engelsman AF; Özyilmaz A; van der Horst-Schrivers AN; Meijer K; van Dam GM; Pol RA; de Borst MH; Kruijff S
    Ann Surg Oncol; 2017 Jan; 24(1):15-22. PubMed ID: 27459979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.
    Narayan R; Perkins RM; Berbano EP; Yuan CM; Neff RT; Sawyers ES; Yeo FE; Vidal-Trecan GM; Abbott KC
    Am J Kidney Dis; 2007 Jun; 49(6):801-13. PubMed ID: 17533023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
    Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
    Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice variation in the treatment of patients with renal hyperparathyroidism: a survey-based study in the Netherlands.
    Zhang JLH; Appelman-Dijkstra NM; Fu EL; Rotmans JI; Schepers A
    BMC Nephrol; 2021 Apr; 22(1):150. PubMed ID: 33892650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis.
    Dulfer RR; Koh EY; van der Plas WY; Engelsman AF; van Dijkum EJMN; Pol RA; Vogt L; de Borst MH; Kruijff S; Schepers A; Appelman-Dijkstra NM; Rotmans JI; Hesselink DA; van Eijck CHJ; Hoorn EJ; van Ginhoven TM;
    Langenbecks Arch Surg; 2019 Feb; 404(1):71-79. PubMed ID: 30729318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
    Tominaga Y; Matsuoka S; Uno N; Sato T
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S21-6. PubMed ID: 19032523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease.
    van der Plas W; Kruijff S; Sidhu SB; Delbridge LW; Sywak MS; Engelsman AF
    Surgery; 2021 Feb; 169(2):275-281. PubMed ID: 33059930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of Intraoperative Parathyroid Hormone Assay during Parathyroidectomy in Dialysis and Renal Transplant Patients with Secondary and Tertiary Hyperparathyroidism.
    El-Husseini A; Wang K; Edon A; Saxon D; Lima F; Sloan D; Sawaya BP
    Nephron; 2018; 138(2):119-128. PubMed ID: 29131092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism.
    Kim WW; Rhee Y; Kim BS; Kim K; Lee CR; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY
    Endocr J; 2019 Oct; 66(10):881-889. PubMed ID: 31189770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study.
    Frey S; Goronflot T; Blanchard C; Kerleau C; Gourraud PA; Wargny M; Caillard C; Hourmant M; Figueres L; Mirallié É;
    Langenbecks Arch Surg; 2022 Sep; 407(6):2489-2498. PubMed ID: 35596781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.